BR112018008111A2 - métodos, kits, agentes e aparelhos para transdução - Google Patents
métodos, kits, agentes e aparelhos para transduçãoInfo
- Publication number
- BR112018008111A2 BR112018008111A2 BR112018008111A BR112018008111A BR112018008111A2 BR 112018008111 A2 BR112018008111 A2 BR 112018008111A2 BR 112018008111 A BR112018008111 A BR 112018008111A BR 112018008111 A BR112018008111 A BR 112018008111A BR 112018008111 A2 BR112018008111 A2 BR 112018008111A2
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- methods
- reagents
- cell
- kits
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000026683 transduction Effects 0.000 title abstract 2
- 238000010361 transduction Methods 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002463 transducing effect Effects 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00041—Use of virus, viral particle or viral elements as a vector
- C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção refere-se a métodos para a transdução de uma pluralidade de células em uma composição de células, tal como uma população de linfócitos, contendo partículas virais. em alguns aspectos, métodos e reagentes fornecidos para a transdução de populações celulares envolvem a ligação de agentes a uma molécula sobre a superfície das células. em alguns casos, os reagentes são reagentes de multimerização e o um ou mais agentes são multimerizados reversivelmente se ligando ao reagente. em alguns aspectos, o agente multimerizado pode prover a transdução e/ou expansão ou proliferação ou outra estimulação de uma população de células, e então tais agentes podem ser removidos por ruptura da ligação reversível. são também fornecidos composições, aparelho e métodos de uso dos mesmos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245265P | 2015-10-22 | 2015-10-22 | |
US201662305989P | 2016-03-09 | 2016-03-09 | |
US201662369020P | 2016-07-29 | 2016-07-29 | |
PCT/IB2016/001605 WO2017068419A2 (en) | 2015-10-22 | 2016-10-20 | Methods, kits, agents and apparatuses for transduction |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018008111A2 true BR112018008111A2 (pt) | 2018-11-06 |
Family
ID=57471925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008111A BR112018008111A2 (pt) | 2015-10-22 | 2016-10-20 | métodos, kits, agentes e aparelhos para transdução |
Country Status (13)
Country | Link |
---|---|
US (2) | US11248238B2 (pt) |
EP (1) | EP3365453A2 (pt) |
JP (2) | JP7195141B2 (pt) |
KR (1) | KR20180108567A (pt) |
CN (2) | CN108474002B (pt) |
AU (2) | AU2016341527B2 (pt) |
BR (1) | BR112018008111A2 (pt) |
CA (1) | CA3002742A1 (pt) |
HK (1) | HK1258932A1 (pt) |
MA (1) | MA45426A (pt) |
MX (3) | MX2018004871A (pt) |
RU (2) | RU2021134624A (pt) |
WO (1) | WO2017068419A2 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6362543B2 (ja) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離 |
EP3132247B1 (en) | 2014-04-16 | 2021-08-18 | Juno Therapeutics GmbH | Methods, kits and apparatus for expanding a population of cells |
JP7195141B2 (ja) * | 2015-10-22 | 2022-12-23 | ジュノ セラピューティクス ゲーエムベーハー | 形質導入のための方法、キット、作用物質および装置 |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
AR111625A1 (es) | 2017-04-27 | 2019-07-31 | Juno Therapeutics Gmbh | Reactivos de partículas oligoméricas y métodos de uso de los mismos |
US11464800B2 (en) | 2018-02-09 | 2022-10-11 | Immatics US, Inc. | Methods for manufacturing T cells |
US20210163893A1 (en) | 2018-08-09 | 2021-06-03 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
KR102159737B1 (ko) | 2018-12-28 | 2020-09-24 | 강원대학교산학협력단 | 스트렙택틴 접합된 양자점 및 그 제조방법 |
CN110129370B (zh) * | 2019-05-06 | 2021-07-20 | 山东昂科诺生物科技有限公司 | 一种car-t毒性指示细胞的快速构建方法 |
EP3980530A1 (en) * | 2019-06-07 | 2022-04-13 | Juno Therapeutics, Inc. | Automated t cell culture |
JP2023511024A (ja) * | 2019-12-30 | 2023-03-16 | サン-ゴバン パフォーマンス プラスティックス コーポレイション | 細胞形質導入のための容器及び方法 |
AU2021220875A1 (en) | 2020-02-12 | 2022-09-29 | Juno Therapeutics, Inc. | CD19-directed chimeric antigen receptor T cell compositions and methods and uses thereof |
KR20220152227A (ko) | 2020-02-12 | 2022-11-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Bcma-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도 |
JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
WO2022103756A1 (en) * | 2020-11-13 | 2022-05-19 | Diagnologix, Llc | Artificial virus presenting cells |
JP2024517863A (ja) * | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
WO2023072006A1 (zh) * | 2021-10-25 | 2023-05-04 | 黄�俊 | 多聚体在car表达细胞检测和细胞制备中的应用 |
Family Cites Families (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3539794A (en) | 1967-09-12 | 1970-11-10 | American Cyanamid Co | Self-contained chemiluminescent lighting device |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JP2624470B2 (ja) | 1984-10-02 | 1997-06-25 | バイオジェン インコーポレイテッド | ストレプトアビジン様ポリペプチドの製造 |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (pt) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
DE68918494T2 (de) | 1988-05-17 | 1995-03-23 | Lubrizol Genetics Inc | Pflanzliches Ubiquitinpromotorsystem. |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
US5171081A (en) | 1992-05-29 | 1992-12-15 | Pita Joe W | Chemiluminescent reactive vessel |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
DK0700430T3 (da) | 1993-06-04 | 2005-08-15 | Us Navy | Fremgangsmåder til selektivt af stimulere proliferation af T-celler |
US5686278A (en) | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
US6033907A (en) | 1995-09-29 | 2000-03-07 | Indiana University Foundation | Enhanced virus-mediated DNA transfer |
US7083979B1 (en) | 1994-03-25 | 2006-08-01 | Indiana University Foundation | Methods for enhanced retroviral-mediated gene transfer |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
EP0815121A4 (en) | 1995-02-09 | 1999-09-01 | Univ Washington | MODIFIED AFFINITY STREPTAVIDINE |
US6022951A (en) | 1995-04-11 | 2000-02-08 | Univ Boston | Streptavidin mutants |
CA2224907A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
EP1686181A3 (en) | 1995-09-29 | 2006-08-09 | Indiana University Research and Technology Corporation | Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
DE19641876B4 (de) * | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
EP0961830A1 (en) | 1997-01-29 | 1999-12-08 | Neurosearch A/S | EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES |
AU6701498A (en) | 1997-03-14 | 1998-09-29 | Trustees Of Boston University | Multiflavor streptavidin |
US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
WO2000043551A1 (en) | 1999-01-26 | 2000-07-27 | Cornell Research Foundation, Inc. | Determining viral load in double negative t cells |
BR0009403A (pt) | 1999-02-04 | 2001-11-27 | Technion Res & Dev Foundation | Método de expansão/conservação das células detronco hemopoiéticas indiferenciadas ou dascélulas progenitoras, método de preparação deum meio condicionado de célula estomacal útil naexpansão/conservação das células de troncohemopoiéticas indiferenciadas ou das célulasprogenitoras, método de transplante de célulasde tronco hemopoiéticas indiferenciadas ou decélulas progenitoras em um recipiente, tampão debiorreator e biorreator |
DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
JP2005536184A (ja) | 2002-03-01 | 2005-12-02 | エルドマン,ヴォルカー,エー. | ストレプトアビジン結合ペプチド |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
BR0312935A (pt) * | 2002-07-17 | 2005-06-21 | Cytos Biotechnology Ag | Partìcula semelhante a vìrus, muteìna, vetores para produzir a referida partìcula e proteìna recombinante, composição, processo para produção de fileira ordena e repetitva de antìgeno, molécula de ácido nucléico, célula hospedeira, método para produção da referida partìcula e uso da composição de vacina |
ES2375724T3 (es) | 2002-09-27 | 2012-03-05 | The General Hospital Corporation | Dispositivo microflu�?dico para seperación de células y sus usos. |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US7795024B2 (en) | 2003-05-02 | 2010-09-14 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
CA2525519A1 (en) | 2003-05-08 | 2004-12-02 | Xcyte Therapies, Inc. | Generation and isolation of antigen-specific t cells |
EP1690090A1 (en) | 2003-11-20 | 2006-08-16 | Biosensor Applications Sweden AB (Publ) | Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture |
SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
US7592431B2 (en) | 2004-02-26 | 2009-09-22 | Immunovative Therapies, Ltd. | Biodegradable T-cell Activation device |
ATE428931T1 (de) | 2004-06-03 | 2009-05-15 | Meso Scale Technologies Llc | Verfahren zur durchführung von vollbluttests |
JP5255841B2 (ja) | 2004-10-15 | 2013-08-07 | ジェネンコー・インターナショナル・インク | 競合示差スクリーニング |
WO2006058226A2 (en) | 2004-11-24 | 2006-06-01 | The Trustees Of Boston University | Modified dimeric streptavidins and uses thereof |
ES2766123T3 (es) | 2004-12-10 | 2020-06-11 | Peter Maccallum Cancer Inst | Métodos y composiciones para inmunoterapia adoptiva |
US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
CN101267834B (zh) * | 2005-09-28 | 2013-06-05 | 赛托斯生物技术公司 | 白介素-1偶联物及其用途 |
US7704708B2 (en) | 2006-02-13 | 2010-04-27 | Uti Limited Partnership | Monomeric streptavidin muteins |
US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
WO2007117602A2 (en) | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation and use of human regulatory t cells |
US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
CA2915560A1 (en) | 2006-10-17 | 2008-04-24 | Tomoaki Fujioka | Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides |
CN101568834A (zh) | 2006-11-02 | 2009-10-28 | 协和梅迪克斯株式会社 | 待测组分的免疫测定方法 |
AU2007353319A1 (en) | 2006-11-15 | 2008-11-20 | Invitrogen Dynal As | Methods for reversibly binding a biotin compound to a support |
US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
KR20080076622A (ko) | 2007-02-16 | 2008-08-20 | 포항공과대학교 산학협력단 | 올리고머화된 단백질 전달체와 이를 이용한 세포내바이러스 벡터 전달 방법 |
EP2617827A1 (en) | 2007-03-26 | 2013-07-24 | Celexion, LLC | Method for displaying engineered proteins on a cell surface |
DK2141997T3 (da) | 2007-03-30 | 2013-02-11 | Sloan Kettering Inst Cancer | Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter |
EP2167536A1 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
US8735330B2 (en) | 2007-08-20 | 2014-05-27 | Nextera As | pVII phage display |
ES2374863T3 (es) | 2007-12-07 | 2012-02-22 | Miltenyi Biotec Gmbh | Centrífuga para separar una muestra en por lo menos dos componentes. |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
NO2222861T3 (pt) | 2007-12-11 | 2018-05-05 | ||
KR20190030779A (ko) | 2008-01-18 | 2019-03-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 체액 내에서 질병 또는 병태의 시그너쳐의 검출 방법 |
WO2009097119A2 (en) | 2008-01-29 | 2009-08-06 | Fred Hutchinson Cancer Research Center | Identification of cd8+ t cells that are cd161hi and/or il18r(alpha)hi and have rapid drug efflux capacity |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
CN101446576B (zh) | 2008-12-29 | 2011-06-22 | 江苏省苏微微生物研究有限公司 | 一种微囊藻毒素-lr单抗免疫亲和柱的制备和使用方法 |
WO2010080032A2 (en) * | 2009-01-09 | 2010-07-15 | Stichting Het Nederlands Kanker Instituut | Bead-assisted viral transduction |
US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
US20120214187A1 (en) | 2009-11-02 | 2012-08-23 | Ffina Biolutions, Llc | Method for Enhancing the Sensitivity of Antibody Based Assays |
US20120321665A1 (en) | 2009-12-14 | 2012-12-20 | Benaroya Research Institute At Virginia Mason | Compositions and methods for treating airway inflammatory diseases |
EP2363501A1 (en) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
EP2982766B1 (en) | 2010-08-06 | 2018-05-23 | Ludwig-Maximilians-Universität München | Identification of t cell target antigens |
CN110452882A (zh) | 2010-12-09 | 2019-11-15 | 宾夕法尼亚大学董事会 | 嵌合抗原受体-修饰的t细胞治疗癌症的用途 |
CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
EP2734538B2 (en) * | 2011-07-18 | 2024-07-03 | IBA Lifesciences GmbH | Method of reversibly staining a target cell |
WO2013038272A2 (en) | 2011-09-13 | 2013-03-21 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
WO2013071154A1 (en) | 2011-11-11 | 2013-05-16 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
AU2013221672B2 (en) | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
JP6362543B2 (ja) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離 |
RU2018130123A (ru) | 2012-05-03 | 2018-11-07 | Фред Хатчинсон Кансэр Рисёч Сентер | Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии |
UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
BR112015000505A2 (pt) | 2012-07-13 | 2017-06-27 | Univ Pennsylvania | método de analisar uma célula t geneticamente modificada para detectar um contaminante |
EP3824905A1 (en) | 2012-08-20 | 2021-05-26 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
EP2711418B1 (en) | 2012-09-25 | 2017-08-23 | Miltenyi Biotec GmbH | Method for polyclonal stimulation of T cells by flexible nanomatrices |
SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
CN105073770B (zh) * | 2012-11-16 | 2019-08-06 | Iba股份有限公司 | 链霉亲和素突变蛋白及其使用方法 |
CN103305464B (zh) | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
FR3010720B1 (fr) | 2013-09-16 | 2017-08-11 | Genethon | Procede de production de virus enveloppes |
EP2886645A1 (en) | 2013-12-20 | 2015-06-24 | Julius-Maximilians-Universität Würzburg | Expansion of human T cells in vitro by bead-bound conventional anti-CD28 monoclonal antibodies |
SG11201605046YA (en) | 2013-12-20 | 2016-07-28 | Hutchinson Fred Cancer Res | Tagged chimeric effector molecules and receptors thereof |
IL307423A (en) | 2014-04-07 | 2023-12-01 | Novartis Ag | Cancer treatment using chimeric antigen receptor (CAR) against CD19 |
EP3132247B1 (en) | 2014-04-16 | 2021-08-18 | Juno Therapeutics GmbH | Methods, kits and apparatus for expanding a population of cells |
MA39867A (fr) * | 2014-04-23 | 2017-03-01 | Juno Therapeutics Inc | Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive |
JP6661544B2 (ja) * | 2014-04-24 | 2020-03-11 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子改変したt細胞の自動生成法 |
CN110819595A (zh) | 2014-04-25 | 2020-02-21 | 蓝鸟生物公司 | 制备过继性细胞疗法的改善方法 |
CN106662584B (zh) | 2014-04-30 | 2020-05-05 | Iba股份有限公司 | 分离靶细胞的方法 |
EP3172228B1 (en) * | 2014-07-25 | 2019-02-27 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
GB201415344D0 (en) * | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
EP4407036A2 (en) | 2014-11-05 | 2024-07-31 | Juno Therapeutics, Inc. | Methods for transduction and cell processing |
JP7068820B2 (ja) | 2014-12-03 | 2022-05-17 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法のための方法および組成物 |
BR112017021500A2 (pt) | 2015-04-08 | 2018-09-25 | Novartis Ag | terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19 |
EP3081740A1 (en) | 2015-04-13 | 2016-10-19 | Geoservices Equipements | System and method for sampling a drilling fluid exiting a wellbore |
WO2016166568A1 (en) | 2015-04-16 | 2016-10-20 | Juno Therapeutics Gmbh | Methods, kits and apparatus for expanding a population of cells |
JP7195141B2 (ja) * | 2015-10-22 | 2022-12-23 | ジュノ セラピューティクス ゲーエムベーハー | 形質導入のための方法、キット、作用物質および装置 |
MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
US20180355014A1 (en) | 2015-12-03 | 2018-12-13 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
SG11201807286WA (en) | 2016-03-19 | 2018-10-30 | F1 Oncology Inc | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
KR20190098747A (ko) | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
AR111625A1 (es) | 2017-04-27 | 2019-07-31 | Juno Therapeutics Gmbh | Reactivos de partículas oligoméricas y métodos de uso de los mismos |
JP2021505168A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 操作されたt細胞の組成物を製造するための方法 |
US20210163893A1 (en) | 2018-08-09 | 2021-06-03 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
WO2020089343A1 (en) | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
-
2016
- 2016-10-20 JP JP2018521109A patent/JP7195141B2/ja active Active
- 2016-10-20 AU AU2016341527A patent/AU2016341527B2/en active Active
- 2016-10-20 MX MX2018004871A patent/MX2018004871A/es unknown
- 2016-10-20 RU RU2021134624A patent/RU2021134624A/ru unknown
- 2016-10-20 RU RU2018118574A patent/RU2761555C2/ru active
- 2016-10-20 BR BR112018008111A patent/BR112018008111A2/pt active Search and Examination
- 2016-10-20 WO PCT/IB2016/001605 patent/WO2017068419A2/en active Application Filing
- 2016-10-20 CN CN201680075275.9A patent/CN108474002B/zh active Active
- 2016-10-20 CN CN202310552883.6A patent/CN116875635A/zh active Pending
- 2016-10-20 MA MA045426A patent/MA45426A/fr unknown
- 2016-10-20 US US15/770,177 patent/US11248238B2/en active Active
- 2016-10-20 EP EP16805495.5A patent/EP3365453A2/en active Pending
- 2016-10-20 KR KR1020187014395A patent/KR20180108567A/ko not_active Application Discontinuation
- 2016-10-20 CA CA3002742A patent/CA3002742A1/en active Pending
-
2018
- 2018-04-19 MX MX2022010687A patent/MX2022010687A/es unknown
- 2018-04-19 MX MX2022010686A patent/MX2022010686A/es unknown
-
2019
- 2019-01-28 HK HK19101411.8A patent/HK1258932A1/zh unknown
-
2022
- 2022-01-18 US US17/578,425 patent/US20220243223A1/en active Pending
- 2022-11-04 JP JP2022177039A patent/JP2023011856A/ja active Pending
-
2023
- 2023-07-20 AU AU2023206191A patent/AU2023206191A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2761555C2 (ru) | 2021-12-09 |
RU2021134624A (ru) | 2022-03-15 |
US11248238B2 (en) | 2022-02-15 |
US20220243223A1 (en) | 2022-08-04 |
CN116875635A (zh) | 2023-10-13 |
AU2016341527B2 (en) | 2023-04-27 |
AU2016341527A1 (en) | 2018-05-10 |
MX2018004871A (es) | 2018-11-09 |
MA45426A (fr) | 2019-05-01 |
KR20180108567A (ko) | 2018-10-04 |
JP2018534928A (ja) | 2018-11-29 |
WO2017068419A2 (en) | 2017-04-27 |
RU2018118574A (ru) | 2019-11-25 |
JP7195141B2 (ja) | 2022-12-23 |
CN108474002A (zh) | 2018-08-31 |
CN108474002B (zh) | 2023-05-23 |
WO2017068419A3 (en) | 2017-05-26 |
AU2023206191A1 (en) | 2023-10-05 |
MX2022010686A (es) | 2022-09-26 |
NZ741861A (en) | 2024-02-23 |
CA3002742A1 (en) | 2017-04-27 |
EP3365453A2 (en) | 2018-08-29 |
MX2022010687A (es) | 2022-09-26 |
JP2023011856A (ja) | 2023-01-24 |
US20200017880A1 (en) | 2020-01-16 |
HK1258932A1 (zh) | 2019-11-22 |
RU2018118574A3 (pt) | 2020-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008111A2 (pt) | métodos, kits, agentes e aparelhos para transdução | |
BR112018008061A2 (pt) | métodos para a cultura de células e kits e aparelhos para os mesmos | |
BR112018008081A2 (pt) | métodos para a cultura de células e kits e aparelho para os mesmos | |
BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
GB2525104A (en) | Massively parallel single cell analysis | |
BR112018004181A2 (pt) | anticorpos anti-lag-3 | |
BR112021020608A8 (pt) | Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit | |
PH12019502415A1 (en) | Oligomeric particle reagents and methods of use thereof | |
BR112015001620A2 (pt) | composição de meio de cultura, e método para cultivo de célula ou tecido usando-se dita composição | |
EP4303314A3 (en) | Polypeptide tagged nucleotides and use thereof in nucleic acid sequencing by nanopore detection | |
BR112018010410A2 (pt) | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 | |
BR112019008560A2 (pt) | célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação | |
MX2016016904A (es) | Analisis de secuencias de acidos nucleicos. | |
EP4339288A3 (en) | Oligonucleotide probes and uses thereof | |
WO2018132739A3 (en) | T cell receptors that bind to ny-eso-1 and methods of use thereof | |
EP4257596A3 (en) | Coumarin compounds and their uses as fluorescent labels | |
WO2015200893A3 (en) | Methods of analyzing nucleic acids from individual cells or cell populations | |
BR112015030972A8 (pt) | células sc-beta e composições e métodos para geração das mesmas | |
MY190837A (en) | Polymethine compounds and their use as fluorescent labels | |
BR112016019940A2 (pt) | edição de genoma sem nucleases | |
WO2015112767A3 (en) | Novel reverse transcriptases for use in high temperature nucleic acid synthesis | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
WO2016100438A3 (en) | Polymerase compositions and methods of making and using same | |
WO2019100079A8 (en) | Compositions for improving car-t cell functionality and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: JUNO THERAPEUTICS GMBH (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |